Phospholipid synthesis is activated in Fra-1 or c-Fos-containing human breast tumor biopsies as compared to non-pathological specimens.

<p>(<b>A</b>) Phospholipid labeling capacity was determined in TH prepared from the 5 non-pathological (white columns) and 8 tumor specimens (black columns) shown in <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0053211#pone-0053211-g007" target="_blank">Figure 7</a>. Results are the mean cpm incorporated into phospholipids/mg protein ± SD of 2 experiments performed in triplicate with each sample. (<b>B</b> and <b>C</b>) Black columns show the phospholipid labeling capacity (mean cpm incorporated into phospholipids/mg TH protein ± SD of 2 experiments performed in triplicate) of tumor samples #5 (<b>B</b>) and #6 (<b>C</b>) in TH (TTH), MF (TMF), 1M KCl-stripped MF (TMF+1M KCl) and stripped MF plus 1.5 ng of recombinant Fra-1 or 1 ng of c-Fos/µg of TH. White columns (NTH) show the phospholipid labeling capacity of pooled TH from the 5 non-pathological samples shown in (A). *: p<0.01.